Clinical TrialAnimal StudyHighlightedRandomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogenMHID-8498103PMID: 337420602021Scientific ReportsMiyuki Kubota, Motoko Kawashima, Sachiko Inoue, Toshihiro Imada, Shigeru Nakamura, Shunsuke Kubota, et al.The incidence of dry eye disease is increasing worldwide because of the aging population and increasing use of information technology. Dry eye disease manifests as tear-layer instability and inflammation caused by osmotic hypersensitization in tear fluids; however, to our knowledge, no agent that treats both pathologies simultaneously is available. Molecular hydrogen (H2) is known to be effective
